ARS Pharmaceuticals, Inc. (SPRY)

Market Cap	1.09B
Revenue (ttm)	2.57M
Net Income (ttm)	-49.10M
Shares Out	97.19M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,340,229
Open	12.15
Previous Close	11.78
Day's Range	11.23 - 12.19
52-Week Range	7.55 - 18.51
Beta	1.25
Analysts	Strong Buy
Price Target	26.00 (+131.32%)
Earnings Date	Mar 20, 2025

About SPRY

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRY
• Website: https://ars-pharma.com

Financial Performance

In 2023, ARS Pharmaceuticals's revenue was $30,000, a decrease of -97.72% compared to the previous year's $1.32 million. Losses were -$54.37 million, 56.8% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for SPRY stock is "Strong Buy." The 12-month stock price forecast is $26.0, which is an increase of 131.32% from the latest price.

Price Target

$26.0

(131.32% upside)

Analyst Consensus: Strong Buy